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Abstract
Interleukin (IL-) 36 cytokines (previously designated as novel IL-1 family member cytokines; IL-1F5– IL-1F10) constitute
a novel cluster of cytokines structurally and functionally similar to members of the IL-1 cytokine cluster. The effects of IL-36
cytokines in inflammatory lung disorders remains poorly understood. The current study sought to investigate the effects of
IL-36a (IL-1F6) and test the hypothesis that IL-36a acts as a pro-inflammatory cytokine in the lung in vivo. Intratracheal
instillation of recombinant mouse IL-36a induced neutrophil influx in the lungs of wild-type C57BL/6 mice and IL-1ab
2/2
mice in vivo. IL-36a induced neutrophil influx was also associated with increased mRNA expression of neutrophil-specific
chemokines CXCL1 and CXCL2 in the lungs of C57BL/6 and IL-1ab
2/2 mice in vivo. In addition, intratracheal instillation of IL-
36a enhanced mRNA expression of its receptor IL-36R in the lungs of C57BL/6 as well as IL-1ab
2/2 mice in vivo.
Furthermore, in vitro incubation of CD11c
+ cells with IL-36a resulted in the generation of neutrophil-specific chemokines
CXCL1, CXCL2 as well as TNFa. IL-36a increased the expression of the co-stimulatory molecule CD40 and enhanced the
ability of CD11c
+ cells to induce CD4
+ T cell proliferation in vitro. Furthermore, stimulation with IL-36a activated NF-kBi n
a mouse macrophage cell line. These results demonstrate that IL-36a acts as a pro-inflammatory cytokine in the lung
without the contribution of IL-1a and IL-1b. The current study describes the pro-inflammatory effects of IL-36a in the lung,
demonstrates the functional redundancy of IL-36a with other agonist cytokines in the IL-1 and IL-36 cytokine cluster, and
suggests that therapeutic targeting of IL-36 cytokines could be beneficial in inflammatory lung diseases.
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Introduction
The Interleukin 1 (IL-1) cytokine cluster consists of a network of
agonist, antagonist and receptor molecules that are expressed in
a variety of immune and structural cells [1]. Since its initial
identification as the human leukocytic pyrogen that causes fever
[2], IL-1 has emerged as highly organized facilitator of early
immune events in a plethora of inflammatory diseases [3]. The
role of IL-1 cytokines in the development of acute and chronic
inflammatory disorders of the lung has been extensively docu-
mented and mechanistically characterized in human patients and
in animal models of human lung disorders. For example, increased
levels of IL-1 protein or mRNA, reflective of increased IL-1
cytokine activity, has consistently been observed in tissues from
human patients with inflammatory lung disorders such as asthma
[4–7], acute lung injury [8–10] and pulmonary fibrosis [11].
Similarly, studies from animal models have demonstrated that IL-
1 cytokines such as IL-1a and IL-1b play critical roles in the
pathogenesis of asthma [12–14], chronic obstructive pulmonary
disease [15,16], acute lung injury [17] and pulmonary fibrosis [18–
20]. In pulmonary infection models, IL-1 promoted or dampened
bacterial clearance from the lungs depending on the bacterial
pathogen [21–23]. While IL-1 induced the recruitment of
neutrophils and pulmonary inflammation during the early stages
of influenza infection in mice [24], it was critical in conferring
protective immunity and enhancing survival of mice during the
later stages of the disease [24–26].
In the last decade, genes encoding a novel cytokine cluster with
structural and functional similarities to interleukin 1 (IL-1) were
discovered and mapped to chromosome 2 in humans and mice
[27–31]. These cytokines, initially termed IL-1 family members 5–
10 (IL1F5– IL1F10) have been recently reclassified according to
an updated cytokine nomenclature scheme [32]. This novel IL-1
like cytokine cluster comprise a collection of agonists IL-36a (IL-
1F6), IL-36b (IL-1F8), IL-36c (IL-1F9), an antagonist IL-36Ra
(IL-36Ra), a nuclear factor IL-37 (IL-1F7) and a functional
heterodimeric receptor complex consisting of a novel receptor IL-
36R (IL-36R) and the adapter molecule IL-1 receptor accessory
protein (IL-1RAcP) [33]. In addition, IL-38 (IL-1F10) has recently
been reported to act as a partial antagonist for IL-36R [34]. The
organization and function of this novel IL-1 like cytokine cluster is
strikingly similar to that of the classical IL-1 cytokine cluster,
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1Ra) which binds to a functional heterodimeric receptor complex
containing IL-1 receptor I (IL-1R1) and IL-1RAcP [35]. Both the
classical and novel IL-1 cytokine cluster agonists induce the
activation of nuclear factor kappa B (NF-kB) and mitogen
associated protein kinase (MAPK) to initiate pro-inflammatory
pathways [31,35]. While the role of classical IL-1 cytokines have
been extensively characterized in the pathogenesis of inflamma-
tory disorders [35,36], the disease-relevant functions of the novel
IL-1 like cytokines (IL-36 cytokines) remain poorly characterized.
We have previously demonstrated that IL-36c is constitutively
expressed and inducibly upregulated in the lungs of mice following
allergic inflammation [37,38]. Airway epithelial cells express IL-
36a and IL-36c [38,39], and the mRNA expression of IL-36a and
IL-36c in airway epithelial cells is increased in response to several
inflammatory stimuli [39,40]. IL-36a and IL-36c directly act on
IL-36R expressing lung fibroblasts to activate NF-kB and MAPK
pathways [39]. We have demonstrated that intratracheal in-
stillation of recombinant IL-36c increased airway hyperrespon-
siveness, induced neutrophil influx and neutrophil-specific che-
mokine production the lungs in vivo [38]. We also demonstrated
that IL-36c activated NF-kB in whole lung tissue and alveolar
macrophage cell lines [38]. Reports from other groups have
demonstrated that the mRNA expression of IL-36a and IL-36c
were also increased in human bronchial epithelial cells exposed to
Pseudomonas aeruginosa [40] and in recurrent respiratory papillomas
[41]. Recent reports have also demonstrated the critical role of IL-
36a, IL-36Ra and IL-36R in the development of psoriasis [42–
45], and that a single amino acid mutation in IL-36Ra can lead to
unchecked cytokine production and pustular psoriasis [46].
Accumulating evidence thus points to the existence of a novel,
underexplored signaling pathway in inflammatory diseases, driven
by the IL-36 cytokine cluster.
Despite the recent progress in elucidating the role of IL-36
cytokines in inflammatory diseases, the in vivo role of IL-36a has
not been extensively investigated in inflammatory lung disorders.
Since multiple cytokines contribute to shaping the overall immune
response in inflammatory disorders, it is necessary to characterize
the proportional contribution and functional redundancy of
individual cytokines to comprehensively understand disease
pathogenesis and devise therapeutic strategies. Since it has been
demonstrated that the mRNA expression of IL-36a in the airway
epithelial cells are increased in response to multiple pro-
inflammatory stimuli [39], we hypothesized that the presence of
IL-36a in the lungs may induce pulmonary inflammation in vivo.
Here we demonstrate that intratracheal instillation of recombinant
mouse IL-36a induces neutrophil influx and the production of
neutrophil-specific chemokines in wild-type mice as well as mice
that lack IL-1a and IL-1b. Furthermore, we also demonstrate that
IL-36a acts directly on CD11c
+ cells to induce the expression of
neutrophil-specific chemokines, T cell costimulatory molecules
and the enhancement of CD4
+ T cell proliferation. Finally, we also
demonstrate that IL-36a activates NF-kB in mouse macrophages.
These results suggest that IL-36a acts as a pro-inflammatory
cytokine in the lung, and that IL-36a could increase inflammatory
responses in disease conditions which involve release of IL-36a
into the lungs.
Materials and Methods
Mice and Procedures
Six to eight week old mice (C57BL/6, C3H/HeJ and OTII
TCR transgenic strains) were purchased from Jackson Laboratory
(Bar Harbor, ME). Mice deficient in IL-1a and IL-1b (IL-1a/b
2/
2) were obtained from Dr. Yoichiro Iwakura [47] and backcrossed
to C57BL/6 background. All mice were housed or bred in specific
pathogen free facility at Massachusetts General Hospital. For
intratracheal instillations, mice were anesthetized with a mixture
of xylazine (8 mg/kg) and ketamine (45 mg/kg). Recombinant
protein preparation or phosphate buffered saline (PBS) controls in
a5 0ml volume were intratracheally (i.t.) instilled using a non-
invasive method. Mice were euthanized with an overdose of
pentobarbital, and tissues were collected at indicated time points
following the procedure. For cell isolation protocols that do not
require isolation of lung tissue, mice were euthanized by carbon-
dioxide asphyxiation.
Ethic Statement
Mice were housed in a temperature controlled specific-pathogen
free facility at Massachusetts General Hospital, and provided
unrestricted access to food and water. All protocols involving the
use of mice were approved by Subcommittee on Research Animal
Care at Massachusetts General Hospital.
Generation of Recombinant IL-36a
A cDNA clone containing full length mouse Il36a (Il1f6, Clone
ID: MMM1013-99829107) was obtained (Open Biosystems). A
PCR product encoding a fusion protein comprised of an N-
terminal FLAG tag followed by the full length coding sequence of
Il36a was generated from this clone using the following restriction-
site engineered primers: Forward 59-CGGAATTCCgattacaaggat-
gacgatgacaagAATAAGGAGAAAGAACTAAGAG-39 and re-
verse 59-AAGGAAAAAAGCGGCCGCTTAATGTACCA-
CAATCATCTC-39. The PCR product and pETDuet-1 vector
(Clontech) were digested with EcoRI and NotI. The digested PCR
product was cloned in-frame with the Histidine purification tags
into the pETDuet-1 vector. The ligation reactions were trans-
formed into E. coli and positive clones were identified. Expression
of His_FLAG_IL-F6 fusion protein was induced in positive clones
by addition of 1 mM Isopropyl b-D-1-thiogalactopyranoside
(IPTG) to log-phase bacterial cultures for 4 h. Following in-
duction, bacterial pellets were frozen at 220uC until protein
isolation. IL-36a was purified from bacterial lysate by Ni
2+ column
chromatography (B-PER 6xHis Fusion Protein Kit, Pierce), and
dialyzed against PBS. Purified, dialyzed IL-36a was treated with
enterokinase (EK-Max, Invitrogen) to cleave His_FLAG tags from
IL-36a protein. Enterokinase was removed from the tag-cleaved
IL-36a preparation by treating with EK-Away (Invitrogen),
according to the manufacturer’s protocols. The purified, tag-
cleaved, enterokinase-removed recombinant IL-36a preparation
was dialyzed and the dialyzed preparation was passed through
aN i
2+ chromatography column. Cleaved tags bound to the
column and the tag-free IL-36a preparations recovered from the
flow-through were dialyzed against PBS, treated with polymyxin-B
agarose beads (Detoxi-Gel, Pierce) to remove LPS contamination.
LPS concentration in the purified IL-36a preparation was ,0.01
EU/mg protein, as measured by Limulus Amebocyte Lysate assay
(Lonza). Tag-removed, polymyxin-treated recombinant mouse IL-
36a was used for in vitro and in vivo studies.
Coomassie Staining
Ten mg of IL-36a was separated on a SDS-polyacrylamide gel
under reducing and denaturing conditions. The gel was soaked in
Fairbank’s Coomassie solution A (25% isopropanol, 10% acetic
acid and 0.05% Coomassie R), microwaved until before boiling
and shaken for 10 minutes at room temperature to stain the gel.
The stain was drained, and the gel was soaked in distilled water
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Western Immunoblotting
Increasing amounts of IL-36a (5, 10 and 20 ng) were separated
on a SDS-polyacrylamide gel under reducing and denaturing
conditions. Proteins were transferred to polyvinylidene fluoride
membranes, probed with rat anti-mouse IL-36a antibody (R&D
Systems, Catalog No. MAB2297) and detected with a horseradish
peroxidase conjugated goat anti-rat secondary antibody (Abcam)
and ECL Plus chemiluminescent detection system (Amersham).
Tissue Collection and Analysis
Mice were euthanized with an overdose of pentobarbital, and
the treacheas were catheterized. Lungs were lavaged three times
with 1 mL of ice cold-PBS. Bronchoalveolar lavage (BAL) fluid
was centrifuged at 1,500 rpm for 15 minutes and the supernatants
were stored at 280uC. Cells in the pellet were used to calculate
total cell numbers (Cellometer, Nexelcom), as well as differential
cell counts on cytospun slides stained with Hema-3 White Cell
Differential Staining Kit (Fisher). More than 100 cells were
counted per sample by light microscopy to calculate differential
cell counts. Upper right lobe of the lung was collected for RNA
analysis, and the left lung was inflation fixed with 10% neutral
buffered formalin for histological analysis.
RNA Isolation and Quantitative Real-time PCR
Total RNA was isolated from lung tissue using Trizol
(Invitrogen) and cell cultures using RNeasy (Qiagen) and treated
with Amplification grade DNaseI (Invitrogen) according to
manufacturer’s protocols. Equal concentrations of DNaseI treated
RNA was reverse transcribed into cDNA using Taqman Reverse
Transcription reagents (Applied Biosystems) and used as input for
quantitative real-time PCR using Power SYBR Green kit (Applied
Biosystems). Primers used in real-time PCR analyses were
designed using the mouse qPrimerdepot (http://
mouseprimerdepot.nci.nih.gov/). Cycle threshold (CT) values
obtained from the assays were analyzed and reported as copies
of target genes per copy of GAPDH, a housekeeping gene.
Measurement of Protein Levels in the BAL Fluid
Cytometric bead array Flex-kits (BD Biosciences) for IL-1a, IL-
1b, TNFa and CXCL1 were used according to manufacturer’s
protocols to evaluate the protein levels in the BAL fluid recovered
from the mice.
Measurement of Lung Function in Mice
Six to eight week old mice were intratracheally administered
10 mg IL-36a or 50 ml PBS, and lung function measurements were
performed 24 h later using the Flexivent system (Scireq, Montreal,
Quebec, Canada), as described before [38]. Briefly, mice were
anesthetized with an intraperitoneal injection of xylazine (12 mg/
kg) and pentobarbital (70 mg/kg). The trachea of anesthetized
mice was cannulated and the mice were ventilated with 6 ml/kg
tidal volume at 150 breaths per minute. To suppress spontaneous
breathing during measurement of lung function, mice were
intraperitoneally injected with pancuronium bromide (2 mg/kg).
Incremental doses of neublized methacholine were used to
determine total lung resistance and compliance according to the
Snapshot-150 perturbation provided by the Flexivent equipment.
Thirteen data points were collected for each methacholine dose,
and only data with a coefficient of determination greater than 0.95
were included in analyses. The survival of mice during the
procedure was simultaneously monitored using electrocardio-
grams.
Isolation and Culture of CD11c
+ Cells
Splenic CD11c
+ cells were isolated from wildtype C57BL/6
using magnetic separation according to manufacturer’s (Miltenyi
Biotec) protocol. Briefly, single cell suspensions prepared from
spleens of wildtype C57BL/6 mice were incubated with red blood
cell lysis solution (Invitrogen) to lyse RBCs. The resulting cell
suspensions were incubated with mouse anti-CD11c microbeads
(Miltenyi Biotec), and CD11c
+ cells were isolated by two rounds of
positive selection to enhance purity. The purity of isolated CD11c
+
cells were routinely .90%. The isolated CD11c
+ cells were
resuspended in RPMI-1640 media containing 10% heat inacti-
vated fetal bovine serum (FBS), L-glutamine and 1% penicillin-
streptomycin. According to the experiment, aliquots of resus-
pended cells were mixed with various concentrations of IL-36a
(0.1 mg/mL, 1.0 mg/mL or 10.0 mg/mL) or an equivalent volume
of PBS. For RNA isolation, cells mixed with IL-36a or PBS were
plated at a concentration of 2.5610
5 cells per well in a 48-well
plate in a volume of 250 ml. The cells were incubated for 2 hours
to adhere. The media was gently removed from the plates by
pipetting, and the cells were washed once with sterile, cold PBS.
RNA was isolated from the adherent cells using RNeasy RNA
isolation kit (Qiagen) according to manufacturer’s protocols. In
some experiments, the media containing IL-36a was removed
from the wells 2 hours after incubation, replaced with RPMI-1640
growth media and allowed to incubate for an additional 22 hours
before evaluating cell surface expression of co-stimulatory
molecules by flow cytometry.
Isolation and Culture of CD4
+ T Cells
Spleens and pooled lymph nodes from wildtype C57BL/6 mice
were used to isolate CD4
+ cells using magnetic separation
according to manufacturer’s (Miltenyi Biotec) protocol to a routine
purity of .95%. Isolated CD4
+ cells were stained with CFSE
(Celltrace CFSE staining kit, Invitrogen) and resuspended in
culture media. For CD4
+ and CD11c
+ co-culture studies, CD11c
+
cells were isolated using magnetic separation protocols, mixed with
the indicated concentrations of IL-36a, plated at a concentration
of 1610
5 cells per well in a 96-well plate and allowed to adhere for
2 hours. Following incubation, media from the wells was removed
by pipetting, cells were washed once with cold PBS, and 4610
5
CFSE-stained CD4
+ T cells were incubated with the adherent
CD11c
+ cells for 96 hours. Following incubation for 96 h, cells
were removed and analyzed by flow cytometry. To evaluate
antigen-specific responses, isolated splenic CD11c
+ cells were
plated at a concentration of 1610
5 cells per well with indicated
concentrations of IL-36a and 100 ng/mL OVA323-339 for 2 hours.
Following incubation, media from the wells was removed by
pipetting, cells were washed once with cold PBS, and 4610
5
CFSE-stained CD4
+ T cells from OTII TCR transgenic mice
were incubated with the adherent CD11c
+ cells for 96 hours.
Following incubation for 96 h, cells were removed and analyzed
by flow cytometry.
Flow Cytometry
Cells isolated from BAL were incubated with Fc block, followed
by incubation with fluorochrome conjugated antibodies against
mouse CD11c, CD11b (BD Biosciences) or Ly6-G (R&D Systems)
according to standard protocols. For CFSE-based cell proliferation
studies, cells were collected and incubated with Fc block, followed
by incubation with allophycocyanin-conjugated anti-CD4 (BD
Biosciences) antibody. T cell proliferation responses were analyzed
IL-36a and Pulmonary Inflammation
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+ cells based on forward- and side-scatter
properties. Flow cytometry data were acquired by an Accuri C6
flow cytometer (Accuri) and analyzed using CFlow software
(Accuri) or Flowjo (Treestar).
Isolation of Alveolar Macrophages from Naı ¨ve Mice
Naı ¨ve C57BL/6 mice were euthanized with an overdose of
pentobarbital. Lungs of mice were lavaged three times with 1 mL
of ice cold-PBS. Pooled BAL fluids from three mice were
centrifuged at 1,500 rpm for 15 minutes. An aliquot of cells were
used for cytospin analysis. RNA was isolated from the remaining
cells using RNeasy RNA isolation kit (Qiagen). Isolated RNA was
treated with DNaseI, reverse transcribed and the resulting cDNA
was used as the input for PCR.
NF-kB Activation Assays in Mouse Macrophage Cell Lines
A mouse macrophage cell line (RAW-ELAM) stably transfected
with the NF-kB responsive E-Selectin promoter driving the
expression of enhanced green fluorescent protein [48] was used
to investigate if IL-36a induced NF-kB activity in mouse
macrophages. Cells were cultured in RPMI-1640 with 10% fetal
bovine serum and 1% penicillin and streptomycin. One day before
the experiments, cells were plated at a density of 5610
5 cells per
well. Media was removed the day of the experiment, and IL-36a
mixed with media was added to the cells and incubated for 6 h.
After incubation, media was removed and cells were washed twice
with ice-cold PBS. Cells were collected, and eGFP fluorescence
reflective of NF-kB activity was measured using an Accuri C6 flow
cytometer.
Statistical Analysis
Data from BAL cell enumeration experiments and real-time
PCR quantification on lung tissue were analyzed by two-tailed
student’s t-test. Real-time PCR data from cell culture experiments
were analyzed by two tailed student’s t-test. Lung resistance and
compliance measurements were analyzed by two-way repeated
measures ANOVA. Statistical significance was accepted at
P,0.05.
Results
IL-36a Induces Neutrophil Influx in the Lungs of Mice
We and others have previously demonstrated that IL-36c is
predominantly expressed in airway epithelial cells and that i.t.
instillation of IL-36c induces neutrophil influx in the lungs of mice
[38,39]. IL-36a and IL-36c mRNA expression levels are increased
in airway epithelial cells in response to various stimuli [39]. To
investigate if IL-36a induces proinflammatory responses in the
lung in vivo, we generated pure recombinant murine IL-36a
protein (Fig. 1A & 1B). A single i.t. instillation of 10 mg IL-36a
induced neutrophil influx (Fig. 1C) in the lungs of wild-type
C57BL/6 mice 24 h following instillation. As expected, the
majority of cells in the lungs of PBS instilled mice were
macrophages (Fig. 1C). The total number of cells (Fig. 1D),
percentage of neutrophils (Fig. 1E) and the total number of
neutrophils (Fig. 1F) were significantly increased in the lungs of
mice that received i.t. IL-36a compared to mice that received PBS.
Flow cytometric evaluation of BAL cells also revealed that
majority of cells recovered from BAL fluid of IL-36a instilled
mice were CD11c
2CD11b
+Ly6G
+ neutrophils, while a majority
of cells recovered from the BAL fluid of PBS instilled mice were
CD11c
+CD11b
2Ly6G
2 cells, reflective of macrophages (Fig. 1G).
Examination of Hematoxylin & Eosin stained lung sections
revealed significant cellular infiltration in the lungs of IL-36a
instilled mice (Fig. 1H) compared to the lungs of mice that received
PBS. While we used polymyxin-treated, highly pure IL-36a,t o
ensure that the results we obtained are not due to trace amounts of
contaminating LPS from the bacteria-derived IL-36a,w e
performed the same set of experiments in C3H/HeJ mice, which
are unresponsive to LPS due to a spontaneous loss-of-function
mutation in Toll like receptor 4 [49]. It has been previously
demonstrated that LPS does not induce neutrophil influx or the
production of neutrophil-specific chemokines CXCL1 and
CXCL2 in the lungs of C3H/HeJ mice [50]. In the current
study, a single i.t. instillation of 10 mg IL-36a induced neutrophil
influx into the lungs (Fig. S1A), increased the total number of cells
(Fig. S1B), percentage of neutrophils (Fig. S1C) and total number
of neutrophils (Fig. S1D) in the lungs as assessed from BAL fluid
recovered from C3H/HeJ mice 24 h following instillation.
Macrophages were the main cell types present in the BAL fluid
of PBS instilled C3H/HeJ mice. These results strongly suggest that
the neutrophil influx observed in the lungs of mice is due to the
agonist activity of IL-36a and not due to contaminants in the
protein preparation. Taken together, these data demonstrate that
neutrophil influx is the predominant response to overproduction of
IL-36a in the lungs.
IL-36a Induces the Expression of Early Response
Cytokines and Neutrophil Specific Chemokines
To determine IL-36a driven molecular mechanisms that induce
neutrophil influx into the lungs, we collected lung tissue from
wildtype C5BL/6 mice 24 h following a single i.t. instillation of IL-
36a and profiled the mRNA expression of selected cytokines,
chemokines as well as agonists and receptors in the IL-1 cytokine
network. The mRNA expression of the early response cytokine
TNFa was significantly increased in the lungs of mice which
received i.t. instillation of IL-36a, compared to saline controls
(Fig. 2A). Similarly, the mRNA expression of IL-1a (Fig. 2B) and
IL-b (Fig. 2C) were also significantly increased in the lungs of IL-
36a instilled mice, while the expression of IL-36c was unaltered
(Fig. 2D). We did not detect the mRNA expression of other agonist
IL-36 cytokines in the lungs under the conditions used (data not
shown). While the mRNA expression of the classical IL-1 receptor
(IL-1RI) was unchanged (Fig. 2E), the mRNA expression of the IL-
36R, the receptor for IL-36a and IL-36c, was significantly
increased in the lungs of IL-36a instilled mice (Fig. 2F). In
Figure 1. Intratracheal instillation of IL-36a induced neutrophil influx in the lungs of wild-type C57BL/6 mice. A) Coomassie blue
stained gel demonstrating the purity of IL-36a preparation. Ten mg IL-36a was loaded on the lane. B) Western immunoblotting of IL-36a protein
preparation detects a band around 18 KDa, the predicted molecular weight of mouse IL-36a. C) Cytospin preparations demonstrating neutrophil
influx in the BAL fluid recovered from mice 24 h following a single i.t. instillation of PBS or 10 mg IL-36a. D) Total cell counts from BAL fluid recovered
from mice 24 h following a single i.t. instillation of PBS or 10 mg IL-36a. E) Differential cell count percentages and F) Differential cell count numbers in
the BAL fluid recovered from mice 24 h following a single i.t. instillation of PBS or 10 mg IL-36a. *Indicates significant differences (P,0.05) compared
to PBS treated mice. Data represent mean6SEM from 4–5 mice/group. G) Flow cytometry on cells recovered from BAL fluid from mice 24 h following
a single i.t. instillation of PBS or 10 mg IL-36a. A majority of cells from the IL-36a instilled lungs were CD11c
2CD11b
+Ly6G
+ neutrophils. Depicted flow
cytometry plots are representative of 4–5 mice/group. H) Hematoxylin & Eosin stained lung sections isolated from mice 24 h following a single i.t
instillation of PBS or 10 mg IL-36a. Depicted sections are representative of 4–5 mice/group.
doi:10.1371/journal.pone.0045784.g001
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PLOS ONE | www.plosone.org 5 September 2012 | Volume 7 | Issue 9 | e45784Figure 2. Intratracheal instillation of IL-36a increased the mRNA expression of proinflammatory mediators in the lungs of wild-type
C57BL/6 mice. A–H) Transcript expression of early response cytokines (TNFa, IL-1a, IL-1b, IL-36c), the classical IL-1 receptor IL-1R1, the novel IL-1
cytokine cluster receptor IL-36R and the neutrophil specific chemokines CXCL1 and CXCL2 in the lungs of mice 24 h following a single i.t instillation
of PBS or 10 mg IL-36a. Transcript expression was evaluated by SYBR-Green based quantitative real-time PCR. I–K) Protein expression of TNFa, IL-1a,
IL-1b and CXCL1 in the BAL fluid recovered from mice 24 h following a single i.t instillation of PBS or 10 mg IL-36a. Protein expression was quantified
by multiplexed cytometric bead arrays. *Indicates significant differences (P,0.05) compared to PBS treated mice. Data represent mean6SEM from 4–
5 mice/group.
doi:10.1371/journal.pone.0045784.g002
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chemokines CXCL1 (Fig. 2G) and CXCL2 (Fig. 2H) were also
significantly increased in the lungs of IL-36a instilled mice
compared to PBS controls. The protein levels of IL-1a (Fig. 2J)
and CXCL1 (Fig. 2L) were significantly increased in the BAL fluid
recovered from IL-36a instilled mice, however the protein levels of
TNFa and IL-1b were not significantly increased. These results
suggest that by inducing the expression of its receptor (IL-36R),
IL-36a may potentially contribute to the initiation of a feedback
signaling loop to enhance proinflammatory responses. Further-
more, these results also suggest that IL-36a acts on structural or
immune cells in the lung to induce the production of CXCL1 and
CXCL2, leading to neutrophil influx in the lungs.
A Single i.t. Instillation of IL-36a does not Induce Airway
Hyperresponsiveness in Mice
To determine if IL-36a induced proinflammatory effects in the
lungs results in differences in physiological responses, wildtype
C57BL/6 mice were intratracheally instilled with a single dose of
IL-36a. Pulmonary function parameters evaluated 24 h later using
invasive plethysmography revealed that the total lung resistance
(Fig. 3A) and lung compliance (Fig. 3B) were not significantly
different between IL-36a and PBS instilled mice.
IL-36a Induces Neutrophil Influx in the Lungs of IL-1a
and IL-1b Deficient Mice
Agonist members of the IL-1 cytokine network often induce
overlapping and redundant pro-inflammatory responses. For
example, IL-1a and IL-1b can induce neutrophil influx into the
lung and induce the production of a variety of proinflammatory
mediators that are induced by IL-36a and IL-36c. We have
demonstrated that IL-36a and IL-36c induce the production of
IL-1a and IL-1b ([38] and the current study). Therefore, to
determine if IL-1a and IL-1b may also contribute in part to the
IL-36a induced pro-inflammatory responses in the lung, we
performed a single i.t. instillation of IL-36a into the lungs of mice
genetically deficient in both IL-1a and IL-1b (IL-1ab
2/2 mice). A
single i.t. instillation of 10 mg IL-36a induced neutrophil influx
(Fig. 4A) in the lungs of IL-1ab
2/2 mice 24 h following
instillation. The majority of cells in the lungs of PBS instilled
mice were macrophages. The total number of cells (Fig. 4A),
percentage of neutrophils (Fig. 4B) and the total number of
neutrophils (Fig. 4C) were significantly increased in the lungs of
IL-1ab
2/2 mice that received i.t. IL-36a compared to IL-1ab
2/2
mice that received PBS. Flow cytometric evaluation of BAL cells
also revealed that majority of cells recovered from the BAL fluid of
IL-36a instilled mice were CD11c
2CD11b
+Ly6G
+ neutrophils,
while a majority of cells recovered from the BAL fluid of PBS
instilled mice were CD11c
+CD11b
2Ly6G
2 cells (Fig. 4D).
Examination of hematoxylin & eosin stained lung sections also
revealed significant cellular infiltration in the lungs of IL-36a
instilled mice (Fig. 4E) compared to the lungs of mice that received
PBS. These data demonstrate that IL-36a can induce neutrophil
influx in the lungs in an IL-1a/b-independent manner.
IL-36a Induces the Expression of Early Response
Cytokines and Neutrophil Specific Chemokines in the
Lungs of IL-1a and IL-1b Deficient Mice
To determine if IL-36a induced cytokine and chemokine
expression is altered in the absence of IL-1a and IL-1b,w e
collected lung tissue from IL-1ab
2/2 mice 24 h following
a single i.t. instillation of IL-36a and profiled the mRNA
expression of selected cytokines, chemokines as well as agonists
and receptors in the IL-1 cytokine network. The mRNA
expression of the early response cytokine TNFa (Fig. 5A) as well
as IL-36c Fig. (5B) was significantly increased in the lungs of
IL-1ab
2/2 mice i.t. instilled with IL-36a, compared to saline
controls. As expected, mRNA expression of neither IL-1a nor
IL-1b was detected in the lungs of IL-1ab
2/2 mice (data not
shown). While the mRNA expression of the classical IL-1
receptor (IL-1RI) was unchanged (Fig. 5C), the mRNA
expression of IL-36R was significantly increased in the lungs
of IL-36a instilled IL-1ab
2/2 mice (Fig. 5D). In addition, the
mRNA expression of the neutrophil recruiting chemokines
CXCL1 (Fig. 5E) and CXCL2 (Fig. 5F) were also increased in
the lungs of IL-36a instilled IL-1ab
2/2 mice compared to PBS
controls. While TNFa protein levels were increased in the BAL
fluid recovered from the lungs of IL-36a instilled IL-1ab
2/2
mice, the increase was not statistically significant (Fig. 5G).
However, the protein levels of CXCL1 were significantly
increased in the BAL fluid recovered from the lungs of IL-
36a instilled IL-1ab
2/2 mice (Fig. 5H). These results suggest
that IL-36a can induce the expression of its receptor (IL-36R)
and the neutrophil chemokines CXCL1 and CXCL2 in the
absence of both IL-1a and IL-1b.
Figure 3. Intratracheal instillation of IL-36a does not induce
airway hypresponsiveness. A) Total lung resistance and B) lung
compliance were not significantly different in the lungs of IL-36a
challenged mice compared to PBS controls. Airway responses in mice
were measured using invasive plethysmography 24 h following i.t
instillation of IL-36a or PBS. Data presented are percentage changes
from baseline (0mg/mL) measurements. Data represent mean6SEM
from 5–7 mice/group.
doi:10.1371/journal.pone.0045784.g003
IL-36a and Pulmonary Inflammation
PLOS ONE | www.plosone.org 7 September 2012 | Volume 7 | Issue 9 | e45784Figure 4. Intratracheal instillation of IL-36a induced neutrophil influx in the lungs of IL-1ab
2/2 mice. A) Total cell counts from BAL fluid
recovered from mice 24 h following a single i.t. instillation of PBS or 10 mg IL-36a. B) Differential cell count percentages and C) Differential cell count
numbers in the BAL fluid recovered from mice 24 h following a single i.t. instillation of PBS or 10 mg IL-36a. *Indicates significant differences (P,0.05)
compared to PBS treated mice. Data represent mean6SEM from 3–4 mice/group. D) Flow cytometry on cells recovered from BAL fluid from mice 24 h
following a single i.t. instillation of PBS or 10 mg IL-36a. A majority of cells from the IL-36a instilled lungs were CD11c
2CD11b
+Ly6G
+ neutrophils.
Depicted flow cytometry plots are representative of 3–4 mice/group. H) Hematoxylin & Eosin stained lung sections isolated from mice 24 h following
a single i.t instillation of PBS or 10 mg IL-36a. Depicted sections are representative of 3–4 mice/group.
doi:10.1371/journal.pone.0045784.g004
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PLOS ONE | www.plosone.org 8 September 2012 | Volume 7 | Issue 9 | e45784IL-36a Induces the mRNA Expression of Early Response
Cytokines and Neutrophil-specific Chemokines in Splenic
CD11c
+ Cells
IL-36a and IL-36c have been reported to be expressed and
inducibly upregulated in airway epithelial cells in response to
various stimuli [39]. In addition, recent reports demonstrated that
bone marrow derived dendritic cells express IL-36R, the receptor
for IL-36a and IL-36c [51]. Since more than 95% of immune cells
in a naı ¨ve mouse lung are CD11c
+ alveolar macrophages, we
hypothesized that under inflammatory conditions, overproduced
IL-36a may activate CD11c
+ cells, leading to the production of
inflammatory mediators that orchestrate the cellular immune
responses in the lung. To determine if IL-36a has direct effects on
cytokine production and antigen-presenting abilities of CD11c
+
cells, we first isolated splenic CD11c
+ cells and incubated them
with increasing concentrations of IL-36a for 2 h. The mRNA
expression of TNFa (Fig. 6A), IL-36c (Fig. 6B), IL-1a (Fig. 6C)
and IL-1b (Fig. 6D) were increased in a dose-dependent manner
upon incubation with IL-36a. However, the expression of neither
IL-1RI (Fig. 6E) nor IL-36R (Fig. 6F) was increased in CD11c
+
cells upon incubation with IL-36a. It is important to note that the
baseline expression of IL-36R in CD11c
+ cells was relatively high
(,0.3 copies/copy GAPDH, Fig. 6F), suggesting that CD11c
+ cells
may readily respond to IL-36a and IL-36c. In addition, IL-36a
also induced a dose-dependent increase in the mRNA expression
of neutrophil recruiting chemokines such as CXCL1 (Fig. 6G) and
CXCL2 (Fig. 6H) in CD11c
+ cells. These data also demonstrate
that IL-36a directly acts on CD11c
+ cells to induce the production
of neutrophil recruiting chemokines, elucidating a molecular
mechanism that potentially drives the influx of neutrophils to the
lung following i.t. instillation of IL-36a. While the results described
Figure 5. Intratracheal instillation of IL-36a increased the mRNA expression of proinflammatory mediators in the lungs of IL-1ab
2/2
mice. A–F) Transcript expression of early response cytokines (TNFa and IL-36c), the classical IL-1 receptor IL-1R1, the novel IL-1 cytokine cluster
receptor IL-36R and the neutrophil specific chemokines CXCL1 and CXCL2 in the lungs of IL-1ab
2/2 mice 24 h following a single i.t instillation of PBS
or 10 mg IL-36a. Transcript expression was evaluated by SYBR-Green based quantitative real-time PCR. G–H) Protein expression of TNFa and CXCL1 in
the BAL fluid recovered from IL-1ab
2/2 mice 24 h following a single i.t instillation of PBS or 10 mg IL-36a. Protein expression was quantified by
multiplexed cytometric bead arrays. *Indicates significant differences (P,0.05) compared to PBS treated mice. Data represent mean6SEM from 3–4
mice/group.
doi:10.1371/journal.pone.0045784.g005
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PLOS ONE | www.plosone.org 9 September 2012 | Volume 7 | Issue 9 | e45784Figure 6. IL-36a induced the expression of proinflammatory cytokines and chemokines in splenic CD11c
+ cells. A–H) Transcript
expression of early response cytokines (TNFa, IL-1a, IL-1b, IL-36c), the classical IL-1 receptor IL-1R1, the novel IL-1 cytokine cluster receptor IL-36R as
well as the neutrophil specific chemokines CXCL1 and CXCL2 in splenic CD11c
+ cells 2 h following incubation with increasing concentrations of IL-
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+ cells, we also
demonstrate that alveolar macrophages isolated from the lungs
of naı ¨ve wild-type mice (Fig. 6I) express IL-1R1, IL-36R and IL-
1RAcP (Fig. 6J). In addition to previous reports demonstrating IL-
36R expression in BMDCs and T cells, here we show that alveolar
macrophages also have the molecular machinery to respond to IL-
36 cytokines. Further studies are required to determine if other
cells that infiltrate the lung during an immune response also
express IL-36R.
IL-36a Induces the Expression of co-stimulatory
Molecules in Splenic CD11c
+ Cells and Enhances CD4
+ T
Cell Proliferation
Activation and excessive proliferation of T cells is a critical
component in the pathogenesis of a multitude of inflammatory
disorders, including lung disorders such as asthma. A recent report
demonstrated that CD4
+ T cells and CD11c
+ cells express IL-36R,
the receptor for IL-36a and the other IL-36 cytokines [51]. To
determine if IL-36a regulated T cell proliferation by modulating
costimulatory molecule expression in APCs, we incubated splenic
CD11c
+ cells with increasing concentrations of IL-36a and
measured the mRNA expression of costimulatory molecules at
earlier timepoints and cell surface expression of the costimulatory
molecules at the later timepoints. While incubation of CD11c
+
cells with IL-36a did not induce the mRNA expression of CD80
(Fig. 7A) or CD86 (Fig. 7B) in CD11c
+ cells 2 h following
incubation, the expression of the co-stimulatory molecule CD40
was significantly increased in a dose-dependent manner (Fig. 7C).
Incubation of splenic CD11c
+ cells with IL-36a for 2 h was
sufficient to induce a modest, but dose-dependent increase in the
percentage of CD80
+CD86
+ cells 24 hours later (Fig. 7D).
Furthermore, incubation of splenic CD11c
+ cells with IL-36a for
2 h also significantly increased cell surface CD80 expression and
a modest, but significant increase in cell surface CD86 expression
24 hours later (Fig. 7E). In addition, the proliferation of CD4
+ T
cells was proportionally increased when co-cultured with CD11c
+
cells pre-incubated with increasing concentrations of IL-36a
(Fig. 8A). Antigen-specific CD4
+ T cell proliferation was also
proportionally increased when CD4
+ T cells from OVA-specific
OTII TCR transgenic mice were co-cultured with CD11c
+ cells
pre-incubated with increasing concentrations of IL-36a and a fixed
concentration of OVA323–339 peptide, the cognate antigen. Since
the IL-36a containing media was removed from the CD11c
+ cells
before addition of CD4
+ cells, these data suggest that IL-36a
induced expression of costimulatory molecules or mediators may
indirectly contribute to T cell proliferation responses.
IL-36a Induces the Activation of NF-kB in Mouse
Macrophage Cell Lines
Previous studies have reported that agonist IL-36 cytokines such
as IL-36a and IL-36c induce NF-kB activation in Jurkat cells
transfected with IL-36R [31]. We have previously demonstrated
that IL-36c induces the activation of NF-kB in macrophage cell
lines in a dose-dependent manner [38]. Here, we demonstrate that
similar to IL-36c, IL-36a also induces the activation of NF-kBi n
a mouse macrophage cell line (Fig. 9). These data suggest that IL-
36a induced NF-kB activity may be a critical mechanism in
driving the production of proinflammatory mediators by macro-
phages and proliferation of T cells by enhancing the stimulatory
properties of dendritic cells.
Discussion
The current study demonstrates that IL-36a acts as a pro-
inflammatory cytokine in the lungs independent of both IL-1a
and IL-1b. Intratracheal instillation of IL-36a induced neutro-
phil influx and increased the expression of pro-inflammatory
cytokines and chemokines in the lungs of wild-type C57BL/6
mice as well as mice deficient in both IL-1a and IL-1b. IL-36a
acted directly on CD11c
+ antigen presenting cells to induce the
production of early response cytokines and neutrophil-specific
chemokines. In addition, IL-36a increased the expression of T
cell co-stimulatory molecules on CD11c
+ cells and enhanced
their ability to stimulate CD4
+ T cell proliferation. Stimulation
of a macrophage cells line with IL-36a induced NF-kB
activation. Collectively, these data suggest that disease-induced
overproduction of IL-36a in the lungs may play an important
role in inflammatory lung disease.
Intratracheal instillation of IL-36a induced neutrophil influx in
the lungs of wildtype and IL-1ab
2/2 mice. Transgenic mice that
conditional overexpress IL-1b in the airway epithelium have
neutrophil influx, increased mucus production and the develop-
ment of emphysematous and fibrotic changes in the lung [52].
Prior reports also demonstrated that intratracheal administration
of IL-1 induced neutrophil influx into the lungs of mice [53], and
that IL-1 is necessary for lipopolysaccharide (LPS) mediated
neutrophil influx in the murine lung [54,55]. We previously
reported that intratracheal administration of IL-36c also induced
neutrophil influx into the lungs and the expression of neutrophil-
specific chemokines [38]. Here we show that IL-36a also resulted
in neutrophil chemotaxis in the lungs, along with an increase in
the mRNA expression of the classical IL-1 agonists IL-1a and IL-
1b in wild-type mice. This supports our previous findings [38] and
those of others [39] demonstrating that agonist IL-36 cytokines
induce the production of classical IL-1 cytokines. Importantly, in
the current study intratracheal instillation of IL-36a induced
neutrophil influx into the lungs of IL-1ab
2/2 mice, suggesting that
IL-36a driven neutrophil recruitment to the lungs is independent
of IL-1a and IL-1b.
The mRNA expression of early response cytokines such as
TNFa, IL-1a and IL-1b were increased in the lungs of wildtype
mice following intratracheal instillation of IL-36a. These results
are consistent with our previous reports demonstrating that i.t.
instillation of IL-36c into the lungs of mice induced the production
of IL-1a in a dose-dependent manner [38]. While the mRNA
expression of IL-1R1 was unchanged, the expression of IL-36R
was significantly increased in the lungs of IL-36a treated mice,
demonstrating that IL-36a can induce the expression of its own
receptor in lung tissue either by directly acting on structural or
immune cells in the lung, or indirectly by inducing the production
of other mediators in the lung that increase IL-36R expression.
Since the expression of IL-36R was also induced in the lungs of IL-
36a instilled IL-1ab
2/2 mice, it is possible to speculate that
neither IL-1a nor IL-1b contribute to IL-36a driven IL-36R
expression. IL-1 induced the mRNA expression of multiple
36a. Transcript expression was evaluated by SYBR-Green based quantitative real-time PCR. *Indicates significant differences (P,0.05) compared to
0 mg/mL group. Data represent mean6SD of quadruplicate samples from one of two representative experiments. I) Diff-quik stained cells from
cytospun BAL cells from the lungs of naı ¨ve mice demonstrates that the majority of lung resident immune cells are alveolar macrophages. J) PCR on
cDNA from naı ¨ve mouse alveolar macrophages demonstrating the constitutive mRNA expression of an endogenous control (b-actin), IL-1R1, IL-36R
and IL-1RAcP. Image of a DNA electrophoresis gel has been color-inverted for clarity. bp – base pairs.
doi:10.1371/journal.pone.0045784.g006
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PLOS ONE | www.plosone.org 11 September 2012 | Volume 7 | Issue 9 | e45784Figure 7. IL-36a induced the expression of T cell costimulatory molecules in splenic CD11c
+ cells. A–C) Transcript expression of the co-
stimulatory molecules CD80, CD86 and CD40 in splenic CD11c
+ cells 2 h following incubation with increasing concentrations of IL-36a. Transcript
expression was evaluated by SYBR-Green based quantitative real-time PCR. *Indicates significant differences (P,0.05) compared to 0 mg/mL group.
Data represent mean6SD from quadruplicate samples from one of two representative experiments. D) Flow cytometric evaluation of splenic CD11c
+
cells 24 h following incubation with increasing concentrations of IL-36a for 2 h. E) Cell surface expression of co-stimulatory molecules in splenic
CD11c
+ cells 24 h following incubation with increasing concentrations of IL-36a for 2 h. MFI – mean fluorescence intensity. *Indicates significant
differences (P,0.05) compared to 0.1 mg/mL group. Data represent mean6SD from triplicate samples from one of two representative experiments.
doi:10.1371/journal.pone.0045784.g007
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[52]. Furthermore, overexpression of IL-1b in the airway
epithelium increased the mRNA expression of CXCL1, CXCL2,
CCL2 and CCL7 chemokines and the accumulation of neutro-
phils in the lungs of mice [59]. Increased mRNA expression of
CXCL1 and CXCL2 in the lungs of IL-36a instilled wildtype as
well as IL-1ab
2/2 mice in the current study suggests that IL-36a
can induce the expression of neutrophil-specific chemokines in the
lungs independent of IL-1a and IL-1b.
We have previously demonstrated that a single intratracheal
instillation of IL-36c induces airway hyperresponsiveness in
response to aerosolized methacholine [38]. However, in the
current study, a single i.t. instillation of a similar amount of IL-36a
did not increase airway hyperresponsiveness. This discrepancy
could be due to inherent differences in the ability of IL-36a and
IL-36c in inducing AHR. For example, we have shown that unlike
IL-36c, IL-36a is not constitutively expressed in lungs [38].
Furthermore, the magnitude of induction of IL-36a mRNA in
response to cytokines and other inflammatory stimuli appears to
be consistently lower than that of IL-36c mRNA expression in
airway epithelial cells [39], bone marrow derived dendritic cells
(BMDCs) and T cells [51]. Therefore, it is possible that a higher
concentration of IL-36a is required to produce similar magnitude
of responses driven by IL-36c at a lower concentration. In
addition, the discrepancy could also be due to differences in AHR-
specific genetic susceptibilities between A/J mice used in our
previous report [38] and the C57BL/6 strain of mice used in this
study.
Figure 8. Incubation with IL-36a enhances the ability of splenic CD11c
+ cell mediated CD4
+ T cell proliferation. A) Flow cytometric
evaluation of CD4
+ T cell proliferation responses induced by IL-36a stimulated splenic CD11c
+ cells. Splenic CD11c
+ cells were incubated with
increasing doses of IL-36a for 2 h. Following incubation, media containing IL-36a was removed and CFSE-labeled CD4
+ T cells were co-cultured with
IL-36a stimulated CD11c
+ cells. CFSE dilution was used to evaluate T cell proliferation responses 96 h following co-culture. CD4
+ T cell proliferation
was proportional to the concentration of IL-36a used for stimulating CD11c
+ cells used in the co-culture. Flow cytometry plot presented is
representative of quadruplicate samples in one out of two independent experiments. B) Flow cytometric evaluation of antigen-specific CD4
+ T cell
proliferation responses induced by IL-36a stimulated splenic CD11c
+ cells. Splenic CD11c
+ cells were incubated with increasing doses of IL-36a and
100 ng/mL OVA323-339 for 2 h. Following incubation, media containing IL-36a and the OVA peptide was removed and CFSE-labeled CD4
+ T cells from
OTII TCR transgenic mice were co-cultured with IL-36a stimulated, OVA peptide pulsed CD11c
+ cells. CFSE dilution in the culture was used to evaluate
T cell proliferation responses 96 h following co-culture. CD4
+ T cell proliferation was proportional to the concentration of IL-36a used for stimulating
CD11c
+ cells used in the co-culture. Flow cytometry plot presented is representative of quadruplicate samples in one out of two independent
experiments.
doi:10.1371/journal.pone.0045784.g008
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PLOS ONE | www.plosone.org 13 September 2012 | Volume 7 | Issue 9 | e45784IL-36a acted directly on splenic CD11c
+ cells to induce the
production of neutrophil-specific chemokines. A recent report
demonstrated that IL-36R was expressed in murine BMDCs and
CD4
+ T cells and that the stimulation of BMDCs with IL-36a, IL-
36b and IL-36c induced the production of multiple cytokines and
chemokines [51]. In the current study we demonstrate that IL-36a
acts directly on splenic CD11c
+ cells to induce the production of
the neutrophil-specific chemokines CXCL1, CXCL2 as well as
other early response cytokines such as TNFa, IL-1a and IL-1b.
Interestingly, the mRNA expression of neither IL-1R1 nor IL-36R
was increased in IL-36a stimulated splenic CD11c
+ cells under the
conditions tested. Since we observed increased IL-36R expression
in whole lung tissue following a single IL-36a challenge, we
speculate that IL-36a either directly increases IL-36R in non-
CD11c
+ cells in the lung, or induces the production of another
endogenous mediator from an IL-36a responsive, non-CD11c
+
cell type in the lungs to increase IL-36R mRNA expression in vivo.
Furthermore, we have also demonstrated that similar to splenic
CD11c
+ cells, alveolar macrophages from naı ¨ve mice also express
IL-36R mRNA at levels higher than IL-1R1, suggesting that
alveolar macrophages are poised to respond to IL-36 cytokines
released into the lung airspaces.
IL-36a acted directly on CD11c
+ cells to induce the
expression of co-stimulatory molecules that regulate T cell
activation and proliferation. While activation and proliferation
of T cells are essential to confer protection against certain
pathogens, aberrant activation and proliferation of T cells leads
to detrimental responses in lung diseases such as asthma [60].
Apart from T cell receptor activation, engagement of co-
stimulatory molecules expressed on T cells (such as CD28 and
CD40L) with those expressed on antigen presenting cells (such
as CD80, CD86 and CD40) are critical for T cell activation
and proliferation [61]. Previous reports have demonstrated that
IL-1b induces antigen-specific proliferation of CD4+ T cells
during the primary and secondary (memory) immune responses
[62], and that CD4
+ T cells from IL-1ab
2/2 mice are defective
in proliferation and the production of T helper 2 (Th2)
cytokines [13]. It has also been demonstrated that IL-1a
induced CD40 expression in human dendritic cells in vitro [63].
Consistent with a recent report [51], we also found that IL-36a
directly induced the mRNA expression of CD40 in CD11c
+
cells. Although both CD80 and CD86 mRNA were constitu-
tively expressed in CD11c
+ cells in our experiments, mRNA
expression was not significantly increased 2 h following
stimulation with IL-36a. However, we found that the cell
surface expression of CD80 and CD86 were increased in splenic
CD11c
+ cells 24 hours following 2 hours of stimulation with IL-
36a. We also found that CD4
+ T cell proliferation responses
were enhanced when co-cultured with IL-36a stimulated
CD11c
+ cells, suggesting that IL-36a mediated upregulation of
costimulatory molecules may be important for T cell pro-
liferation. Interaction of CD40 with CD40L is important for
Th1 cell differentiation [64]. Vigne et al., recently demonstrated
that IL-36b (IL-1F8) increased CD40 mRNA expression and
enhanced Th1 responses in vivo [51]. Collectively, these data
support an important role of novel IL-1 cytokine agonists in
regulating T cell activation and proliferation by modulating
antigen presentation and co-stimulatory abilities of APCs.
Experiments in the current study were performed using splenic
CD11c
+ cells, which may have different cytokine secretion and
antigen-presenting capabilities than CD11c
+ cells that reside in
or are recruited to the lungs during pulmonary inflammation
[65]. We have shown that alveolar macrophages isolated from
naı ¨ve wild-type mice express IL-36R and IL-1RAcP, suggesting
Figure 9. IL-36a directly induced NF-kB activation in mouse
macrophage cell lines. A) Cells from a mouse macrophage NF-kB
reporter cell line (RAW-ELAM cells) were stimulated with increasing
concentrations of IL-36a. Green fluorescent protein (GFP) expression,
indicative of NF-kB activation, was increased in a dose-dependent
manner upon incubation with IL-36a. Flow cytometry plot presented is
representative of triplicate samples in one out of two independent
experiments.
doi:10.1371/journal.pone.0045784.g009
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cytokines in the lung. While we speculate that the responses of
lung CD11c
+ cells to IL-36a would be largely similar to the
responses reported in the current study, further studies are
required to determine the functional effects of IL-36a on lung
specific CD11c
+ cells and subsets.
IL-36a activated NF-kB in mouse macrophages. Activation of
NF-kB in the lungs leads to airway inflammation, mucus cell
metaplasia and the production of proinflammatory cytokine and
chemokines [66–68]. Agonist members of the novel IL-1
cytokine cluster induced NF-kB and MAPK activation in Jurkat
cells transfected with IL-36R [31]. We previously demonstrated
that IL-36c induced NF-kB activation in mouse macrophages
following in vitro stimulation and in total lung tissue following
a single intratracheal challenge with IL-36c [38]. In addition,
IL-36c also induced NF-kB activation in lung fibroblasts [39].
Consistent with these findings, IL-36a also induced NF-kB
activation in mouse macrophages, which may be a potential
mechanism driving the production of neutrophil-specific che-
mokines from macrophages and dendritic cells in the lung
resulting in recruitment of neutrophils. Furthermore, these
results also confirm previous findings that NF-kB is a critical
signaling molecule downstream of both IL-1R1 and IL-36R
mediated responses.
To date, the role of IL-36a has not been examined in human
inflammatory lung disease. It is interesting that very high
concentrations of the IL-36 agonists including IL-36a are
required to stimulate in vitro cellular responses [30,31]. A recent
report demonstrates that truncation variants of IL-36a, IL-36b
and IL-36c exert enhanced agonist activity in vitro, suggesting
that a yet unidentified protease may process these cytokines to
more biologically potent forms in vivo [69]. Although the
magnitude of the cellular responses was enhanced by the
truncation variants, the underlying IL-36 cytokine driven
mechanisms such as NF-kB activation remain similar. There-
fore, we conclude that although that the results reported in this
study using the full-length IL-36a reflect the functional
consequences of IL-36a overproduction in the lung, further
studies are required to determine if the truncated versions of IL-
36a proteins would induce more severe inflammation in the
lung in vivo. Furthermore, since the IL-36 cytokine agonists do
not possess a leader peptide that is necessary for cytokine
secretion [70], the in vivo mechanisms by which these cytokines
are released into the extracellular spaces such as BAL fluid
remains to be clarified. While there are several reports
demonstrating increased mRNA expression of novel IL-1
cytokine agonists, there is a paucity of reports on the in vivo
detection of the cytokines at the protein level in extracellular
spaces. Among the several mechanisms by which IL-1b has
been proposed to become available in the extracellular space
[71–75], plasma membrane breakdown has been suggested to
be the most plausible mechanism by which intracellular IL-36a
could become available in the extracellular space [76]. The
current study determined that IL-36a acts as a pro-inflamma-
tory cytokine in the lung, and that IL-36a may increase
inflammatory responses in disease conditions which involve
release of IL-36a into the lungs.
Supporting Information
Figure S1 Intratracheal instillation of IL-36a induced neutrophil
influx in the lungs of endotoxin resistant C3H/HeJ mice. A) Total
cell counts from BAL fluid recovered from mice 24 h following
a single i.t. instillation of PBS or 10 mg IL-36a. C) Differential cell
count percentages and D) Differential cell count numbers in the
BAL fluid recovered from mice 24 h following a single i.t.
instillation of PBS or 10 mg IL-36a. *Indicates significant
differences (P,0.05) compared to PBS treated mice. Data
represent mean6SEM from 4–5 mice/group.
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